中药联合依诺肝素对髋关节置换术后血浆凝血酶原时间、活化部分凝血活酶时间、纤维蛋白原、D-二聚体含量影响的临床研究

目的:研究中药联合依诺肝素对髋关节置换术后血浆凝血酶原时间(Prothrombin Time,PT)、活化部分凝血活酶时间(Activated Partial Thromboplastin Time,APTT)、纤维蛋白原(Fibrinogen,FIB)、D-二聚体(D-Dimer)水平的影响。方法:研究对象选取时间:2016年7月-2019年7月,研究对象为符合纳入与排除标准的86例髋关节置换术患者,术后应用依诺肝素43例为对照组,应用中药联合依诺肝素治疗43例观察组,回顾分析术后2周深静脉血栓形成率、术后首日与术后2周的血浆指标(PT、APTT、FIB、D-Dimer)含量、不良反应。结果:观察组患者术后2周下肢深静脉血栓形成率小于对照组,P<0.05。术后首日,两组患者血浆PT、APTT、FIB、D-Dimer含量比较差异无统计学意义,P>0.05。治疗2周结束后,观察组血浆PT、APTT、FIB、D-Dimer含量优于对照组,P<0.05。两组患者用药不良反应比较差异无统计学意义,P>0.05。结论:髋关节置换术后采取中药联合依诺肝素治疗,可帮助患者改善血浆PT、APTT、FIB、D-Dimer等指标水平,用药安全性高,能够降低患者术后深静脉血栓发生率,值得推广与应用。

The effect of TCM plus enoxaparin on contents of PT,APTT,FIB,D-Dimer in plasma after hip replacement

Objective:To investigate effect of TCM plus enoxaparin on contents of PT,APTT,FIB,D-Dimer in plasma after hip replacement.Methods:86 cases were divided into two groups,43 cases in each group.The control group was treated with enoxaparin after operation,and the observation group was treated with TCM medicine plus enoxaparin.Results:The lower extremity deep vein thrombosis rate was lower in the observation group than that in the control group at 2 weeks after operation,P<0.05.On the first postoperative day,there was no significant difference in the levels of PT,APTT,FIB,and D-Dimer between two groups,P>0.05.After 2 weeks of treatment,the plasma levels of PT,APTT,FIB,and D-Dimer in the observation group were better than the control group,P<0.05.There was no significant difference in adverse drug reactions between two groups,P>0.05.Conclusion:TCM plus enoxaparin can improve plasma PT,APTT,FIB,D-Dimer and other indicators after hip joint replacement,reduce the incidence of postoperative deep vein thrombosis.